高级检索
当前位置: 首页 > 详情页

The challenge of managing comorbidities: a case report of primary Sjogren's syndrome in a patient with acute intermittent porphyria.

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. [2]Department of Rheumatology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. [3]School of First Clinical Medical College, Southern Medical University, Guangzhou, Guangdong, China. [4]Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang, Hebei, China. [5]Geriatrics, First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
出处:
ISSN:

关键词: acute intermittent porphyria primary Sjogren's syndrome autoimmune disease treatment

摘要:
Acute intermittent porphyria (AIP) is a rare inherited metabolic disease associated with heme metabolism. Primary Sjogren's syndrome (PSS) is a common autoimmune disease. The combined presence of AIP and PSS complicates treatment. A rare case of concomitant AIP and PSS is reported in this paper. A 30-year-old woman with AIP had recurrent acute abdominal pain, nausea and vomiting, constipation, persistent chest, back, and waist pain, red urine, positivity for porphobilinogen (PBG) in urine and a pathogenic mutation of the HMBS gene. Two and a half years after she was diagnosed with AIP, she was diagnosed with PSS based on dryness of the eyes and mouth, the elevation of immunoglobulins (IgG and IgA) and positive results on an anti-SS-A antibody test, an anti-SS-B antibody test, Schirmer's test and a labial gland biopsy. A mutation in the HMBS gene was detected in the patient and her cousin, but the patient had more severe AIP and more severe symptoms (such as epilepsy and a limp), which may be related to the co-morbidity of PSS. According to her PSS activity score, the patient had an ESSDAI score of 9 and required systemic treatment. However, potential medications were limited by AIP, so mycophenolate mofetil was eventually added to delay the progression of the primary disease. 2020, International Research and Cooperation Association for Bio & Socio - Sciences Advancement.

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
第一作者:
第一作者机构: [1]Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
通讯作者:
通讯机构: [1]Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. [*1]Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2021 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号